| Year |
Citation |
Score |
| 2023 |
Sharma R, Incoronato A, Zhang C, Jayanthan A, Shah R, Narendran A. Establishment of a t(11;19), KMT2A Rearranged B-ALL Cell Line for Preclinical Evaluation and Novel Therapeutics Development for Refractory Infant Leukemia. Journal of Pediatric Hematology/Oncology. 45: e750-e756. PMID 37494611 DOI: 10.1097/MPH.0000000000002697 |
0.656 |
|
| 2023 |
Kosnopfel C, Wendlinger S, Niessner H, Siewert J, Sinnberg T, Hofmann A, Wohlfarth J, Schrama D, Berthold M, Siedel C, Sauer B, Jayanthan A, Lenz G, Dunn SE, Schilling B, et al. Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion. Journal of Experimental & Clinical Cancer Research : Cr. 42: 175. PMID 37464364 DOI: 10.1186/s13046-023-02755-5 |
0.332 |
|
| 2021 |
Banderali U, Jain M, Thakur S, Jayanthan A, Belke DD, Giles WR, Narendran A. The T-type Calcium Channel Cav3.1 in Y79 Retinoblastoma Cells is Regulated by the Epidermal Growth Factor Receptor via the MAPK Signaling Pathway. Current Eye Research. 1-10. PMID 34674590 DOI: 10.1080/02713683.2021.1988982 |
0.55 |
|
| 2021 |
Thakur S, Ruan Y, Jayanthan A, Boklan J, Narendran A. Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib. Current Cancer Drug Targets. PMID 33949932 DOI: 10.2174/1568009621666210504085527 |
0.624 |
|
| 2020 |
Huynh MM, Pambid MR, Jayanthan A, Dorr A, Los G, Dunn SE. The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials. Expert Opinion On Investigational Drugs. PMID 32869671 DOI: 10.1080/13543784.2020.1818067 |
0.366 |
|
| 2020 |
Thakur S, Ruan Y, Zhang C, Lun X, Jayanthan A, Narendran A. Human SNF5 arming of double-deleted vaccinia virus shows oncolytic and cytostatic activity against central nervous system atypical teratoid/rhabdoid tumor cells. Cancer Gene Therapy. PMID 32678303 DOI: 10.1038/S41417-020-0199-2 |
0.637 |
|
| 2020 |
Beeram M, Wang JS, Mina LA, Patnaik A, Pambid MR, Jayanthan A, Huynh M, Dunn SE, Los G, Dorr A. First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer. Journal of Clinical Oncology. 38: TPS1110-TPS1110. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps1110 |
0.395 |
|
| 2019 |
Jayanthan A, Hofmann B, Meier-Stephenson V, Perinpanayagam M, Dunn SE, Boklan J, Trippett TM, Truong TH, Narendran A. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells. Journal of Pediatric Hematology/Oncology. PMID 30702467 DOI: 10.1097/Mph.0000000000001416 |
0.64 |
|
| 2018 |
Swift L, Jayanthan A, Ruan Y, Anderson R, Boklan J, Trippett T, Narendran A. Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib. Targeted Oncology. PMID 30446871 DOI: 10.1007/S11523-018-0603-0 |
0.666 |
|
| 2016 |
Singh A, Meier-Stephenson V, Jayanthan A, Narendran A. In Vitro Sensitivity Profiling Of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library To Identify Agents For Future Therapeutic Studies. Current Cancer Drug Targets. PMID 27875952 DOI: 10.2174/1568009617666161122145219 |
0.712 |
|
| 2015 |
Ruan Y, Kovalchuk A, Jayanthan A, Lun X, Nagashima Y, Kovalchuk O, Wright JR, Pinto A, Kirton A, Anderson R, Narendran A. Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy. Neuro-Oncology. 17: 822-31. PMID 25395461 DOI: 10.1093/Neuonc/Nou310 |
0.661 |
|
| 2014 |
Jayanthan A, Ruan Y, Truong TH, Narendran A. Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents. Plos One. 9: e102741. PMID 25048812 DOI: 10.1371/Journal.Pone.0102741 |
0.678 |
|
| 2014 |
Perinpanayagam M, Kovalchuk A, Ruan Y, Kang S, Jayanthan A, Kovalchuk O, Boklan J, Narendran A. Establishment and Drug Sensitivity, Gene Expression and Epigenetic Characterization of a Pediatric Leukemia Cell Line (POETIC1) with Primary Resistance to Decitabine Blood. 124: 983-983. DOI: 10.1182/Blood.V124.21.983.983 |
0.68 |
|
| 2014 |
Ruan Y, Jayanthan A, Cooper T, Narendran A. 588 Neddylation as a therapeutic target in refractory pediatric malignancies: Evaluation of the activating enzyme inhibitor MLN4924 European Journal of Cancer. 50: 189-190. DOI: 10.1016/S0959-8049(14)70714-2 |
0.588 |
|
| 2014 |
Reimer J, Kovulchuk A, Ruan Y, Shah R, Jayanthan A, Perinpanayagam M, Truong T, Auer-Grzesiak I, Luider J, Kovulchuk O, Trippett T, Narendran A. 411 Druggability of p16 deleted pediatric leukemia: The novel cell line POETIC3 identifies potential agents and drug combinations for mechanism based targeted therapeutics European Journal of Cancer. 50: 131. DOI: 10.1016/S0959-8049(14)70537-4 |
0.634 |
|
| 2013 |
Lun X, Ruan Y, Jayanthan A, Liu DJ, Singh A, Trippett T, Bell J, Forsyth P, Johnston RN, Narendran A. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Molecular Oncology. 7: 944-54. PMID 23816608 DOI: 10.1016/J.Molonc.2013.05.004 |
0.629 |
|
| 2013 |
Singh A, Lun X, Jayanthan A, Obaid H, Ruan Y, Strother D, Chi SN, Smith A, Forsyth P, Narendran A. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. Molecular Oncology. 7: 497-512. PMID 23375777 DOI: 10.1016/J.Molonc.2013.01.001 |
0.714 |
|
| 2013 |
Jayanthan A, Cooper TM, Hoeksema KA, Lotfi S, Woldum E, Lewis VA, Narendran A. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells. Leukemia & Lymphoma. 54: 1505-16. PMID 23176524 DOI: 10.3109/10428194.2012.752079 |
0.711 |
|
| 2013 |
Jayanthan A, Ruan Y, Hagerty M, Shah R, Truong T, Lewis VA, Boklan J, Trippett T, Gore L, Narendran A. In Vitro Growth Inhibition, Target Modulation and Drug Synergy In Pediatric Leukemia By The Novel Proteasome Inhibitor Carfilzomib Blood. 122: 2673-2673. DOI: 10.1182/Blood.V122.21.2673.2673 |
0.732 |
|
| 2013 |
Ruan Y, Liu D, Jayanthan A, Truong T, Boklan J, Narendran A. Abstract C205: Cytotoxicity and target modulation in pediatric solid tumors by the proteasome inhibitor carfilzomib. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C205 |
0.715 |
|
| 2013 |
Hagerty M, Jayanthan A, Ruan Y, Trippett T, Narendran A. Abstract C175: Effective targeting of PI3K/mTOR pathways with GDC-0980 in FLT-3 mutant pediatric leukemia. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C175 |
0.697 |
|
| 2012 |
Hasselblatt M, Kordes U, Wolff J, Jeibmann A, Frühwald M, Paulus W, Isken S, Siebert R, Schneppenheim R, Benesch M, Fleischhack G, Gruhn B, Schlegel P, Witt O, Holter W, ... ... Jayanthan A, et al. Atypical Teratoid Rhabdoid Tumor (Atrt) Neuro-Oncology. 14. PMID 22745951 DOI: 10.1093/Neuonc/Nos091 |
0.581 |
|
| 2012 |
Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, et al. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Stem Cells (Dayton, Ohio). 30: 1064-75. PMID 22415968 DOI: 10.1002/Stem.1081 |
0.68 |
|
| 2012 |
Banderali U, Jayanthan A, Hoeksema KA, Narendran A, Giles WR. Ion channels in pediatric CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) cells: potential targets for novel therapeutic agents. Journal of Neuro-Oncology. 107: 111-9. PMID 21971736 DOI: 10.1007/S11060-011-0735-X |
0.689 |
|
| 2012 |
Jayanthan A, Cooper T, Dunn SE, Lewis VA, Narendran A. Cooperative Lethality of Polo-Like Kinases (PLK) and Aurora Kinases (AK) in Refractory Pediatric Leukemia Blood. 120: 3573-3573. DOI: 10.1182/Blood.V120.21.3573.3573 |
0.708 |
|
| 2012 |
Leonard A, Wolff J, Sengupta R, Marassa J, Piwnica-Worms D, Rubin J, Pollack I, Jakacki R, Butterfield L, Okada H, Fangusaro J, Warren KE, Mullins C, Jurgen P, Julia S, ... ... Jayanthan A, et al. HIGH GRADE GLIOMAS Neuro-Oncology. 14: i56-i68. DOI: 10.1093/Neuonc/Nos102 |
0.534 |
|
| 2011 |
Jayanthan A, Bernoux D, Bose P, Riabowol K, Narendran A. Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. Cancer Cell International. 11: 44. PMID 22206574 DOI: 10.1186/1475-2867-11-44 |
0.699 |
|
| 2011 |
Banderali U, Belke D, Singh A, Jayanthan A, Giles WR, Narendran A. Curcumin blocks Kv11.1 (erg) potassium current and slows proliferation in the infant acute monocytic leukemia cell line THP-1. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 28: 1169-80. PMID 22179005 DOI: 10.1159/000335850 |
0.674 |
|
| 2011 |
Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A. Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. Oncotargets and Therapy. 4: 149-68. PMID 21949608 DOI: 10.2147/Ott.S21553 |
0.68 |
|
| 2011 |
Singh A, Jayanthan A, Farran A, Elwi AN, Kim SW, Farran P, Narendran A. Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition. Leukemia Research. 35: 1649-57. PMID 21798596 DOI: 10.1016/J.Leukres.2011.06.035 |
0.682 |
|
| 2011 |
Blackmore C, Jayanthan A, Ujack E, Magliocco T, Narendran A. Analysis of multiple growth regulatory proteins using dissociable staining antibody arrays on solid tumor biopsy specimens Fetal and Pediatric Pathology. 30: 177-188. PMID 21355677 DOI: 10.3109/15513815.2010.547558 |
0.626 |
|
| 2011 |
Jayanthan A, Incoronato A, Singh A, Blackmore C, Bernoux D, Lewis V, Stam R, Whitlock JA, Narendran A. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement. Pediatric Blood & Cancer. 56: 353-60. PMID 21225911 DOI: 10.1002/Pbc.22760 |
0.67 |
|
| 2011 |
Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford, England). 50: 417-9. PMID 20693540 DOI: 10.1093/rheumatology/keq218 |
0.53 |
|
| 2011 |
Štrbák V, Eduardsen K, Larsen SL, Novak I, Lambert IH, Hoffmann EK, Pedersen SF, Li A, Banerjee J, Leung CT, Peterson-Yantorno K, Stamer WD, Civan MM, Ellis DZ, Schedlbauer A, ... ... Jayanthan A, et al. The Na (+)/H+ Exchanger Nhe-1, A Crucial Cellular Integrator Controlled By Its Membrane Environment Cellular Physiology and Biochemistry. 28: 1295-1330. DOI: 10.1159/000335868 |
0.506 |
|
| 2011 |
Štrbák V, Eduardsen K, Larsen SL, Novak I, Lambert IH, Hoffmann EK, Pedersen SF, Li A, Banerjee J, Leung CT, Peterson-Yantorno K, Stamer WD, Civan MM, Ellis DZ, Schedlbauer A, ... ... Jayanthan A, et al. Contents Vol. 28, 2011 Cellular Physiology and Biochemistry. 28. DOI: 10.1159/000335863 |
0.494 |
|
| 2010 |
Jayanthan A, Miettunen PM, Incoronato A, Ortiz-Neira CL, Lewis VA, Anderson R, Frohlich DE, Narendran A. Childhood acute lymphoblastic leukemia (ALL) presenting with severe osteolysis: a model to study leukemia-bone interactions and potential targeted therapeutics. Pediatric Hematology and Oncology. 27: 212-27. PMID 20367265 DOI: 10.3109/08880011003663382 |
0.637 |
|
| 2010 |
Jayanthan A, Singh A, Lewis VA, Narendran A. Preclinical Studies of Cytotoxicity, Drug Synergy and Biological Correlates of Clofarabine Against Infant Leukemia Cells Blood. 116: 4342-4342. DOI: 10.1182/Blood.V116.21.4342.4342 |
0.682 |
|
| 2009 |
Jayanthan A, Howard SC, Trippett T, Horton T, Whitlock JA, Daisley L, Lewis V, Narendran A. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leukemia & Lymphoma. 50: 1174-82. PMID 19557638 DOI: 10.1080/10428190902943069 |
0.681 |
|
| 2009 |
Lotfi S, Jayanthan A, Lewis VA, Guilcher G, Squires MS, Cooper T, Narendran A. AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells. Blood. 114: 3078-3078. DOI: 10.1182/Blood.V114.22.3078.3078 |
0.707 |
|
| 2009 |
Miettunen P, Jayanthan A, Incoronato A, Narendran A. An experimental approach to understand tumor initiated processes that result in bone osteolysis in pediatric acute lymphoblastic leukemia patients Bone. 45: S94. DOI: 10.1016/J.Bone.2009.04.143 |
0.593 |
|
| 2008 |
Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment. Journal of Experimental Therapeutics & Oncology. 7: 183-93. PMID 19066127 |
0.558 |
|
| 2008 |
Narendran A, Coppes L, Jayanthan A, Coppes M, Teja B, Bernoux D, George D, Strother D. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics. Journal of Neuro-Oncology. 90: 171-80. PMID 18651103 DOI: 10.1007/S11060-008-9653-Y |
0.687 |
|
| 2008 |
Miettunen P, Jayanthan A, Narendran A. 7.3 Successful use of anakinra, a soluble IL-1 receptor antagonist, in pediatric rheumatic diseases associated macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis Pediatric Rheumatology. 6. DOI: 10.1186/1546-0096-6-S1-S13 |
0.534 |
|
| 2008 |
Jayanthan A, Howard SC, Trippett T, Horton TM, Daisley L, Lewis VA, Narendran A. Targeting the Bcl-2 Family of Proteins in Hodgkin Lymphoma: In Vitro Cytotoxicity, Target Modulation and Drug Combination Studies of the BH3 Mimetic ABT-737 Blood. 112: 3626-3626. DOI: 10.1182/BLOOD.V112.11.3626.3626 |
0.437 |
|
| 2005 |
Hawkins LM, Jayanthan AA, Narendran A. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatric Research. 57: 430-7. PMID 15659698 DOI: 10.1203/01.Pdr.0000153871.45184.19 |
0.69 |
|
| Show low-probability matches. |